CARDIOPROGRESS
Foundation for the advancement of cardiology

Non-cardiac birth defects and long-term risk of cardiovascular hospitalisation Patients with heart defects are at risk of developing cardiovascular disease. Our objective was to determine if non-cardiac birth defects are associated with the risk of cardiovascular hospitalisation.

Urate in Atherosclerotic Plaques Boosts Risk for CV Events Patients with gout and hyperuricemia harboring cardiovascular (CV) monosodium urate (MSU) deposits in atherosclerotic plaques are at an increased risk for major adverse cardiovascular events (MACE).

Don't Overlook Underlying CV Risks In RA Treatmen Patients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated to manage that risk. Rheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic disorders advised.

Microvascular disease and arrhythmias: a renewed focus on the myocardial microvasculature? Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

In Angina, Gene Therapy Coaxes Heart Vessel Growth An experimental new gene therapy has specialists questioning whether heart vessel growth to restore blood flow could actually be possible in refractory angina after bypass surgery.

Prenatal Exercise Cuts Common Pregnancy Complications Moderate-intensity physical activity during pregnancy is known to be safe for the mother and foetus, but does it reduce the risk for medical complications? A new up-to-date review summarises the data, including seven meta-analyses, which establishes that prenatal exercise prevents hypertension disorders in pregnancy (HDP), including gestational diabetes mellitus (GDM). These are the most common medical complications of pregnancy, affecting up to 15% of pregnant women.

Heart Failure, Not Stroke, Most Common Complication of A-Fib The lifetime risk of atrial fibrillation (AF) increased from 2000 to 2022 from one in four to one in three, a Danish population-based study of temporal trends found.

Incremental value of machine learning for risk prediction in tetralogy of Fallot Machine learning (ML) can facilitate prediction of major adverse cardiovascular events (MACEs) in repaired tetralogy of Fallot (rTOF). We sought to determine the incremental value of ML above expert clinical judgement for risk prediction in rTOF.

Can Treating Depression Mitigate CVD Risk? Depression is linked to a significantly increased risk for cardiovascular disease (CVD), particularly in women, new data from a large retrospective cohort study show. Researchers suggest that screening and treating patients for depression may lead to a decreased incidence of CVD.

Gout Increases the Risk for a Wide Range of Cardiovascular Diseases People with gout are 58% more likely to develop cardiovascular disease (CVD), according to a new analysis. This increased risk was observed across 12 different cardiovascular conditions, including heart failure, arrhythmias, and valve diseases.

New Insight Into CVD, Stroke Risk in Migraine Researchers are unraveling the complex relationship between cardiovascular (CV)- and stroke-related outcomes in migraine with, and without, aura.

How to Get Published in a Specialized Journal Every month, hundreds of manuscripts land in the inboxes of biomedical journals. For example, researchers submitted more than 2200 articles to JAMA Cardiology in 2023. Only 6% of all original research papers were accepted.

Roche Blood Test for Lp(a) Designated Breakthrough Device A blood test that measures lipoprotein(a) [Lp(a)] has received breakthrough device designation from the US Food and Drug Administration. The Tina-quant Lp(a) RxDx assay, developed by Roche in partnership with Amgen, is designed to identify adults with elevated Lp(a) levels who may benefit from lipid-lowering therapies currently in development.

New TAVI Platform Adds More Valve Sizes to Choose From Intermediate valve sizes are at least as safe and effective as the standard sizes now available for transcatheter aortic valve implantation (TAVI), according to an international randomized trial.

World Red Cross Day and Red Crescent Day World Red Cross Day and Red Crescent Day is celebrated on 8 May every year. This date is the birth anniversary of Henry Dunant, who was born on 8 May 1828 at Geneva, Switzerland, and died on 30 October 1910 at Heiden, Switzerland. He was the founder of (ICRC) International Committee of the Red Cross and the recipient of the first Nobel Peace Prize in 1901.

Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis The risk for cardiovascular diseases (CVDs) is lower in patients with seropositive rheumatoid arthritis (RA) who remain on stable disease-modifying antirheumatic drug (DMARD) therapy than in those whose treatment regimen is not stable.

Novel PCSK9 Inhibitor Reduced LDL by 50% Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients with or at a high risk for cardiovascular disease (CVD), new phase 3 results showed.

ACC/AHA Issue Updated Atrial Fibrillation Guideline The American College of Cardiology (ACC), the American Heart Association (AHA), the American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) have issued an updated guideline for preventing and optimally managing atrial fibrillation (AF).

AHA Flags Barriers to Women in Interventional Specialties A new scientific statement from the American Heart Association (AHA) addresses barriers to entry and retention of women in interventional vascular fields, including interventional cardiology, interventional radiology, and vascular surgery, and proposes potential solutions.

New Marker of Cardiovascular Risk Discovered in T2D A significant quantity of dysfunctional monocytes appears to indicate poor cardiovascular prognosis in patients with type 2 diabetes.